Wedbush initiated coverage of Revolution Medicines with an Outperform rating and $41 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RVMD:
- Largest borrow rate increases among liquid names
- Revolution Medicines initiated with an Outperform at Raymond James
- Revolution Medicines price target lowered to $28 from $32 at H.C. Wainwright
- Revolution Medicines announces Horning joined board of directors
- Revolution Medicines completes acquisition of EQRx
